{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:33:57Z","timestamp":1790386437171,"version":"4.1.0"},"reference-count":38,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T00:00:00Z","timestamp":1587686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Dupilumab is the first biological treatment approved for moderate-to-severe atopic dermatitis (AD). Efficacy and safety have been demonstrated in clinical trials, but real-life data is still limited. The objective of this study was to retrospectively evaluate Dupilumab treatment in AD patients in a real-life clinical setting. Effectiveness and safety outcomes were collected at baseline and after 2, 6, 10, 24, 39, and 52 weeks by using clinical scores for disease activity, as well as serological markers. Ninety-four patients from five dermatological hospitals were included. After 24 weeks of treatment, the median Investigator Global Assessment (IGA) and Eczema Area and Severity Index (EASI) showed a significant reduction compared to baseline (3.9 \u00b1 0.7 vs. 1.4 \u00b1 0.8 and 26.5 \u00b1 12.5 vs. 6.4 \u00b1 6.5). Interestingly, we observed rosacea-like folliculitis as an unexpected side effect in 6.4% of patients. Dupilumab proves to be an effective and well-tolerated treatment under real-life conditions. The occurrence of rosacea-like folliculitis warrants further mechanistic investigation.<\/jats:p>","DOI":"10.3390\/jcm9041241","type":"journal-article","created":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T01:29:15Z","timestamp":1588123755000},"page":"1241","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis"],"prefix":"10.3390","volume":"9","author":[{"given":"Tamara","family":"Quint","sequence":"first","affiliation":[{"name":"Department of Dermatology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3488-3345","authenticated-orcid":false,"given":"Patrick M.","family":"Brunner","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5589-1865","authenticated-orcid":false,"given":"Christoph","family":"Sinz","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Steiner","sequence":"additional","affiliation":[{"name":"Institute of Medical Statistics, Medical University Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Ristl","sequence":"additional","affiliation":[{"name":"Institute of Medical Statistics, Medical University Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kornelia","family":"Vigl","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Rudolfstiftung City Hospital, 1030 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0443-8558","authenticated-orcid":false,"given":"Susanne","family":"Kimeswenger","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Kepler University Hospital, 4020 Linz, Austria"},{"name":"Department of Soft Matter Physics, Institute for Experimental Physics, Johannes Kepler University, 4020 Linz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Neubauer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medical University of Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Detlev","family":"Pirkhammer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Rudolfstiftung City Hospital, 1030 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Zikeli","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Wiener Neustadt Public Hospital, 2700 Wiener Neustadt, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfram","family":"Hoetzenecker","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Kepler University Hospital, 4020 Linz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7666-8566","authenticated-orcid":false,"given":"Norbert","family":"Reider","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medical University of Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Bangert","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,4,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jaci.2017.09.044","article-title":"Identification of atopic dermatitis subgroups in children from 2 longitudinal birth cohorts","volume":"141","author":"Paternoster","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/all.13401","article-title":"Epidemiology of atopic dermatitis in adults: Results from an international survey","volume":"73","author":"Barbarot","year":"2018","journal-title":"Allergy"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(15)00149-X","article-title":"Atopic dermatitis","volume":"387","author":"Weidinger","year":"2016","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2310\/6620.2007.06034","article-title":"A population-based survey of eczema prevalence in the United States","volume":"18","author":"Hanifin","year":"2007","journal-title":"Dermatitis"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s40265-014-0219-3","article-title":"Advances in the diagnosis and therapeutic management of atopic dermatitis","volume":"74","author":"Vestergaard","year":"2014","journal-title":"Drugs"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"606","DOI":"10.20344\/amp.11963","article-title":"Update on Atopic Dermatitis","volume":"32","author":"Torres","year":"2019","journal-title":"Acta Med. Port."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"851","DOI":"10.2340\/00015555-3219","article-title":"Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index","volume":"99","author":"Ariens","year":"2019","journal-title":"Acta Derm. Venereol"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): A 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/bjd.16156","article-title":"Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: A placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFE)","volume":"178","author":"Smith","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"adv00014","DOI":"10.2340\/00015555-3368","article-title":"Dupilumab Efficacy and Safety in Adolescents with Moderate-to-Severe Atopic Dermatitis: A Case Series","volume":"100","author":"Mareschal","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jaad.2003.08.003","article-title":"Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)\/American Academy of Dermatology Association \"Administrative Regulations for Evidence-Based Clinical Practice Guidelines\"","volume":"50","author":"Hanifin","year":"2004","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2018.10.032","article-title":"Atopic dermatitis endotypes and implications for targeted therapeutics","volume":"143","author":"Czarnowicki","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/1523-1747.ep12606215","article-title":"In vivo confocal scanning laser microscopy of human skin: Melanin provides strong contrast","volume":"104","author":"Rajadhyaksha","year":"1995","journal-title":"J. Investig. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/bjd.13783","article-title":"Reflectance confocal microscopy for monitoring the density of Demodex mites in patients with rosacea before and after treatment","volume":"173","author":"Sattler","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2307\/2533558","article-title":"Small sample inference for fixed effects from restricted maximum likelihood","volume":"53","author":"Kenward","year":"1997","journal-title":"Biometrics"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Thiboutot, D., Anderson, R., Cook-Bolden, F., Draelos, Z., Gallo, R., Granstein, R., Kang, S., Macsai, M., Gold, L.S., and Tan, J. (2020). Standard Management Options for Rosacea: The 2019 Update by the National Rosacea Society Expert Committee. J. Am. Acad. Dermatol., Epub ahead of print.","DOI":"10.1016\/j.jaad.2020.01.077"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1159\/000345364","article-title":"High-definition optical coherence tomography for the in vivo detection of demodex mites","volume":"225","author":"Maier","year":"2012","journal-title":"Dermatology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/srt.12137","article-title":"Reflectance confocal microscopy vs. standardized skin surface biopsy for measuring the density of Demodex mites","volume":"20","author":"Gurel","year":"2014","journal-title":"Skin Res. Technol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jaad.2019.02.053","article-title":"Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort","volume":"81","author":"Faiz","year":"2019","journal-title":"J. Am. Acad Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/jdv.15609","article-title":"Treatment of atopic dermatitis with dupilumab: Experience from a tertiary referral centre","volume":"33","author":"Olesen","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_23","first-page":"418","article-title":"Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: Daily practice data","volume":"182","author":"Bosma","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/ACI.0000000000000198","article-title":"Biomarkers for atopic dermatitis: A systematic review and meta-analysis","volume":"15","author":"Thijs","year":"2015","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis","volume":"143","author":"Bissonnette","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0091-6749(97)70276-8","article-title":"The relative contribution of IL-4 and IL-13 to human IgE synthesis induced by activated CD4+ or CD8+ T cells","volume":"100","author":"Punnonen","year":"1997","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/all.13984","article-title":"Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis","volume":"75","author":"Bachert","year":"2019","journal-title":"Allergy"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/all.13685","article-title":"Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis","volume":"74","author":"Jonstam","year":"2019","journal-title":"Allergy"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s12325-018-0702-4","article-title":"Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy\/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma","volume":"35","author":"Busse","year":"2018","journal-title":"Adv. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jdermsci.2018.01.016","article-title":"Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis","volume":"90","author":"Wang","year":"2018","journal-title":"J. Dermatol. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e435","DOI":"10.1111\/jdv.15755","article-title":"Pathomechanism of dupilumab-associated inflammatory eye symptoms","volume":"33","author":"Wohlrab","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1038\/jid.2015.141","article-title":"Molecular and Morphological Characterization of Inflammatory Infiltrate in Rosacea Reveals Activation of Th1\/Th17 Pathways","volume":"135","author":"Buhl","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.cyto.2010.08.009","article-title":"Tear cytokines and chemokines in patients with Demodex blepharitis","volume":"53","author":"Kim","year":"2011","journal-title":"Cytokine"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/bjd.16330","article-title":"Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with Demodex and increased interleukin-17 levels?","volume":"178","author":"Thyssen","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Voorberg, A.N., den Dunnen, W.F.A., Wijdh, R.H.J., de Bruin-Weller, M.S., and Schuttelaar, M.L.A. (2019). Recurrence of conjunctival goblet cells after discontinuation of dupilumab in a patient with dupilumab-related conjunctivitis. J. Eur. Acad. Dermatol. Venereol.","DOI":"10.1111\/jdv.15914"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2340\/00015555-3121","article-title":"Eye Complications During Dupilumab Treatment for Severe Atopic Dermatitis","volume":"99","author":"Ivert","year":"2019","journal-title":"Acta Derm. Venereol."},{"key":"ref_38","first-page":"1","article-title":"Rosacea associated with dupilumab therapy","volume":"2019","author":"Heibel","year":"2019","journal-title":"J. Dermatol. Treat."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/4\/1241\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:33:27Z","timestamp":1760366007000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/4\/1241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,24]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,4]]}},"alternative-id":["jcm9041241"],"URL":"https:\/\/doi.org\/10.3390\/jcm9041241","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,24]]}}}